Balversa (erdafitinib) — CareFirst (Caremark)
Pancreatic carcinoma
Initial criteria
- Diagnosis of pancreatic carcinoma with FGFR genetic alterations
- Used as a single agent
- Used as subsequent therapy for recurrent, locally advanced, or metastatic disease
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on current regimen
Approval duration
12 months